Biogen to Cut Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biogen to Cut Jobs

ePT--the Electronic Newsletter of Pharmaceutical Technology

Biogen to Cut Jobs

Biogen Idec (Boston, MA) said last Thursday that it would lay off approximately 17% of its workforce to reduce annual operating costs by $200–300 million.

The downsizing will be part of a restructuring plan conceived after reviews of business processes, geographic locations, and staffing. Cuts will be made at the managerial and staff level, and are expected to equate to approximately 650 jobs, mostly in the San Diego, California, area, and at the company's manufacturing operations at Research Triangle Park, North Carolina.

In addition, the company plans to sell its NICO clinical manufacturing plant in San Diego and property in Oceanside, California. Also on the chopping block is the psoriasis drug, "Amevive," which had revenue of $43 million in 2004. Biogen expects the plan to take effect by the end of the year.

Biogen Idec said that it is considering using the additional funds for new product opportunities and 'the acquisition of products and companies, as well as expanding collaborative research with academic institutions and teaching hospitals."

In related news, Biogen also announced that Michael Gilman, executive vice-president of research, is leaving the company, effective Nov. 8. Alphonse Galdes, vice-president of drug discovery, and Rainer Fuchs, vice-president of research informatics and operations, will take his place in the interim.

–George Koroneos

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here